Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.55 |
| ▸ | TYMS | P04818 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27864170 | 0.85 | PARP14 (0.44) | AKR1B1PTGDR2TYMSENPP2CYP2C9 | |
| SCHEMBL5350725 | 0.76 | TYMS (0.45) | TYMSENPP2CYP2C9ALDH1A1LMNA | |
| SCHEMBL1406039 | 0.75 | PTGDR2 (0.53) | AKR1B1PTGDR2TYMSENPP2CYP2C9 | |
| SCHEMBL3767411 | 0.74 | PTGDR2 (0.67) | AKR1B1PTGDR2CYP2C9S100A4 | |
| SCHEMBL2984548 | 0.73 | MEN1 (0.46) | TYMSENPP2ALDH1A1LMNAMEN1 | |
| SCHEMBL27847166 | 0.72 | PTGDR2 (0.39) | AKR1B1PTGDR2TYMSENPP2CYP2C9 | |
| SCHEMBL13206681 | 0.72 | PTGDR2 (0.86) | AKR1B1PTGDR2CYP2C9 | |
| SCHEMBL16240660 | 0.72 | RHEB (0.44) | — | |
| Azd1981 SCHEMBL30538014 | 0.71 | PTGDR2 (1.00) | AKR1B1PTGDR2CYP2C9 | |
| Azd1981 SCHEMBL1053662 | 0.71 | PTGDR2 (1.00) | AKR1B1PTGDR2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102482214-B | Intermediates and processes for preparing 4- (acetylamino) -3- [ (4-chloro-phenyl) thio ] -2-methyl-1H-indole-1-acetic acid | ASTRAZENECA AB | 2014-08-27 | — | — | CN | disclosed |
| EP-2451780-B1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4-(ACETYLAMINO))-3-[(4-CHLORO-PHENYL)THIO]-2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2451780-B1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4-(ACETYLAMINO))-3-[(4-CHLORO-PHENYL)THIO]-2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| US-8227622-B2 | Pharmaceutical process and intermediates 714 | ASTRAZENECA AB (SE) | 2012-07-24 | — | — | US | disclosed |
| US-8227622-B2 | Pharmaceutical process and intermediates 714 | ASTRAZENECA AB (SE) | 2012-07-24 | — | — | US | disclosed |
| US-8227622-B2 | Pharmaceutical process and intermediates 714 | ASTRAZENECA AB (SE) | 2012-07-24 | — | — | US | disclosed |
| CN-102482214-A | Intermediates and processes for preparing 4- (acetylamino) -3- [ (4-chloro-phenyl) thio ] -2-methyl-1H-indole-1-acetic acid | ASTRAZENECA AB | 2012-05-30 | — | — | CN | disclosed |
| EP-2451780-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4- (ACETYLAMINO) ) -3- [ (4-CHLORO-PHENYL) THIO]-2-METHYL-1H-INDOLE-1-ACETIC ACID | AstraZeneca AB (SE) | 2012-05-16 | — | — | EP | disclosed |
| EP-2025670-B1 | Use of 3-phenylthio-1H-indole-1-acetic acid derivatives as modulators of CRTh2 receptor activity | ASTRAZENECA AB (SE) | 2011-03-16 | — | — | EP | disclosed |
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| WO-2011004182-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4- (ACETYLAMINO) ) -3- [ (4-CHLORO-PHENYL) THIO] -2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | CYP3A4, CYP4A11, CYP4B1 | AKR1B1 298/4885PTGDR2 3430/4885TYMS 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.